Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization

Ophthalmology

Volumn 117, Issue 7, 2010, Pages 1376-1380

  Khurana, Rahul N ^a   Dupas, Bénédicte ^a   Bressler, Neil M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN ANTIBODY;

AGED; ARTICLE; CONTROLLED STUDY; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTERSTITIAL FLUID; MAJOR CLINICAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SENSITIVITY AND SPECIFICITY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TIME DOMAIN OPTICAL COHERENCE TOMOGRAPHY;

AGED; CAPILLARY PERMEABILITY; CHOROID; CHOROIDAL NEOVASCULARIZATION; FALSE POSITIVE REACTIONS; FLUORESCEIN; FLUORESCEIN ANGIOGRAPHY; HUMANS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 77954349362     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.11.039     Document Type: Article

References (11)

1. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
2. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
3. C.D. Regillo, D.M. Brown, P. Abraham PIER Study Group Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2008 239 248
4. S.Y. Cohen, L. Dubois, and R. Tadayoni Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting Am J Ophthalmol 148 2009 409 413
5. A.E. Fung, G.A. Lalwani, and P.J. Rosenfeld An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 2007 566 583
6. K. Sayanagi, S. Sharma, T. Yamamoto, and P.K. Kaiser Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab Ophthalmology 116 2009 947 955
7. Macular Photocoagulation Study Group Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study Arch Ophthalmol 109 1991 1242 1257
8. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy Study Group, Verteporfin in Photodynamic Therapy Study Group Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatmentTAP and VIP report no. 2 Arch Ophthalmol 121 2003 1253 1268
9. Submacular Surgery Trials Research Group Guidelines for interpreting retinal photographs and coding findings in the Submacular Surgery Trials (SST): SST report no. 8 Retina 25 2005 253 268
10. N. Eter, and R.F. Spaide Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy Retina 25 2005 691 696
11. P.A. Keane, R.A. Bhatti, and J.W. Brubaker Comparison of clinically relevant findings from high-speed Fourier-domain and conventional time-domain optical coherence tomography Am J Ophthalmol 148 2009 242 248